AN2 Therapeutics Inc (ANTX)
Healthcare
Biotechnology
5.40 $
+0.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns AN2 Therapeutics Inc (ANTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 55.6% of the shares are freely tradable; institutional investors hold 70.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
70.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
19.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
55.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
36Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vivo Capital, LLC | 8.76 | 3,153,640 | +0.0 | 03/31/2026 |
| COMMODORE CAPITAL LP | 6.48 | 2,333,713 | +0.0 | 03/31/2026 |
| Millennium Management LLC | 6.17 | 2,222,502 | +2,222.8 | 03/31/2026 |
| Spruce Street Capital LP | 4.61 | 1,661,073 | +0.0 | 03/31/2026 |
| Almitas Capital LLC | 4.11 | 1,479,129 | -48.2 | 12/31/2025 |
| Vanguard Group Inc | 3.00 | 1,080,070 | +0.0 | 12/31/2025 |
| Vanguard Capital Management, LLC | 2.81 | 1,011,078 | +0.0 | 03/31/2026 |
| Adage Capital Partners Gp LLC | 2.78 | 1,000,000 | +0.0 | 03/31/2026 |
| Woodline Partners LP | 2.76 | 993,671 | +580.7 | 03/31/2026 |
| Boxer Capital Management, LLC | 2.08 | 749,035 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.